Demant A/S, the Danish global leader in hearing healthcare, has announced a significant cost-reduction program that includes the elimination of approximately 700 positions worldwide. This strategic overhaul comes in the wake of a "turbulent year" characterized by softer industry-wide market growth and a notable dip in profitability. While the measures are designed to reset costs and enhance future profitability, the company has explicitly stated that U.S. hearing care providers should not anticipate adverse effects on their essential services and support, as the reductions are primarily focused on administrative roles outside the United States.
A Challenging Fiscal Year for a Global Leader
The announcement was made in conjunction with the release of Demant’s Annual Report 2025 and its full-year financial results, which presented a mixed financial picture. For the fiscal year 2025, Demant reported a 5% increase in revenue, with organic growth standing at 2%. While these figures align with the company’s twice-revised forecasts, they reflect a challenging environment for the hearing aid industry as a whole. Crucially, Earnings Before Interest and Taxes (EBIT) before special items decreased by approximately 7%, settling at DKK 3.960 billion (approximately US$626 million), resulting in an operating margin of 17.2%. This decline in profitability, despite revenue growth, underscored the necessity of the announced cost-saving initiatives.
Demant, a conglomerate encompassing renowned brands such as Oticon, Bernafon, Sonic, and a vast portfolio of diagnostic and special equipment manufacturers like Interacoustics and Amplivox, holds a pivotal position in the global hearing healthcare landscape. Its performance is often seen as a bellwether for the wider industry. The reported financial figures, while demonstrating resilience in sales volume, revealed the significant pressure on profit margins that has become a recurring theme across the sector.
Macroeconomic Headwinds and Consumer Hesitancy
The "turbulent year" cited by Demant is largely attributed to pervasive macroeconomic uncertainties that have dampened consumer confidence and purchasing power globally. Similar to financial reports from other major hearing aid manufacturers, Demant’s 2025 year-end report specifically highlighted "reduced willingness to invest" and "delayed purchases" as key factors. This trend led to lower-than-normal growth in the overall hearing healthcare market, particularly pronounced in the crucial U.S. market, which subsequently intensified competition among providers.
Søren Nielsen, CEO of Demant, articulated this sentiment during a recent conversation at the U.S. launch of the Oticon Zeal product. Nielsen explained that even in Denmark, a country where approximately half the population receives hearing aids free of charge through public subsidies, the market has experienced stagnation due to economic apprehension. "You don’t take the step [toward getting a hearing aid] if you’re not comfortable about how the world is going to develop," Nielsen commented, emphasizing a global phenomenon. "And we see that worldwide: uncertainty in all parts is causing people to hold back… so they’re just postponing purchases a little bit." This observation underscores a broader shift in consumer behavior, where elective healthcare expenditures, even for essential devices like hearing aids, are being deferred amidst financial caution.
Demant’s Strategic Response: A Comprehensive Profitability Initiative
In response to these market dynamics and the imperative to restore profitability, Demant has initiated a comprehensive cost-saving program designed for long-term impact. The company plans to implement structural changes over the next two years, targeting permanent cost efficiencies across its global operations. The initiative is multifaceted, focusing on several key levers:
- Shifting Work to More Cost-Effective Locations: This involves relocating certain functions to regions where operational costs are lower, leveraging global talent pools more efficiently.
- Prioritizing Activities: A thorough review of all activities will be undertaken to identify and discontinue non-essential functions, ensuring resources are allocated to areas that deliver maximum strategic value.
- Increasing Efforts to Lower Production Costs: This includes optimizing manufacturing processes, exploring new technologies, and streamlining supply chains to reduce the cost of goods sold.
- Tightening Procurement: A more rigorous approach to sourcing and supplier management will be adopted to achieve better terms and reduce input costs.
The most tangible outcome of this initiative is the planned workforce reduction. Demant anticipates that approximately 700 employees globally will be affected by 2026. Of this total, about 150 positions will be cut in Denmark, Demant’s home country. The company projects these measures to yield annual cost savings of around DKK 500 million (approximately US$79 million), with the full effect realized by 2028. Critically, Demant expects to achieve DKK 250 million (approximately US$39 million) in savings as early as 2026, indicating a swift implementation of the initial phases of the program.
Assurances for the U.S. Market and Hearing Care Providers
){kind=logo}
A significant concern for the hearing healthcare community, particularly in the United States, is the potential disruption to customer support and professional services. However, Demant has moved to allay these fears. A representative from Oticon US, speaking to HearingTracker, confirmed that the announced reductions will not "significantly impact the United States." The spokesperson explicitly stated that U.S. hearing care providers should not anticipate cuts to crucial customer-facing roles, including field representatives, customer service personnel, and related support positions.
Instead, the representative clarified that the majority of the job cuts are expected to target administrative positions located outside the U.S. This strategic focus aims to streamline corporate functions and reallocate costs without compromising the direct support infrastructure vital for practitioners. The company’s emphasis on protecting customer-facing roles underscores its commitment to maintaining strong relationships with hearing care professionals, who are critical partners in delivering its products and services to end-users.
The KIND Group Acquisition: A Factor in Administrative Streamlining
While not explicitly mentioned by the Oticon US spokesperson in the context of job cuts, Demant’s acquisition of KIND Group in 2025 may also play a role in the administrative streamlining efforts. KIND Group, one of Germany’s largest dispensing networks with approximately 650 locations, represents a substantial addition to Demant’s retail footprint. Such a large-scale acquisition inevitably leads to a review of overlapping administrative tasks and functions, creating opportunities for consolidation and efficiency gains. It is plausible that some of the administrative positions being reduced globally are a direct or indirect consequence of integrating the KIND Group into Demant’s existing operational structure, further contributing to the rationale behind the organizational staff reductions.
Future Outlook: Modest Market Growth and Improving Profitability
Looking ahead, Demant has provided a cautious yet optimistic outlook for the global hearing aid market. For 2026, the company assumes market value growth of 2-4%, a forecast described as conservative and "temporarily below" its medium- to long-term assumptions, which historically have averaged 4-6% growth over the past decade. This suggests an expectation of continued, albeit subdued, recovery in the immediate future.
)
Demant’s financial guidance for 2026 includes a projected organic growth of 3-6% and an EBIT before special items ranging from DKK 4,100 to DKK 4,500 million (approximately US$648-711 million). The profitability initiative is expected to be a significant contributor to this improved outlook, with an anticipated DKK 250 million (US$39 million) boost to EBIT before special items in 2026, predominantly impacting the second half of the year as the restructuring actions gain momentum. Furthermore, the KIND Group acquisition is forecasted to contribute approximately DKK 300 million (US$47 million) to EBIT before special items in 2026, highlighting the strategic value of this expansion.
Innovation as a Pillar of Growth
Despite the focus on cost efficiency, Demant continues to emphasize innovation as a core driver of future growth. The company recently launched the Oticon Zeal NXT, an instant-fit in-ear hearing aid, at EUHA in Germany in October. Its subsequent U.S. debut two weeks ago in Phoenix was reportedly well-received by attending hearing care professionals. This product, featuring modern connectivity and rechargeability, represents Demant’s ongoing commitment to delivering advanced solutions to consumers. Market analysts are also speculating about the potential launch of a new flagship product line later this year, following the Zeal introduction, which would further solidify Oticon’s competitive position and contribute to the company’s long-term growth objectives.
Broader Industry Implications
Demant’s actions reflect a broader trend across the hearing healthcare industry, where manufacturers are navigating a complex landscape of macroeconomic pressures, evolving consumer expectations, and intense competition. The strategic restructuring, while difficult for affected employees, is a proactive measure to ensure long-term sustainability and competitiveness. By streamlining operations and focusing on core strengths, Demant aims to emerge from this period of adjustment as a more agile and profitable entity, better equipped to serve the evolving needs of the global hearing aid market and its extensive network of hearing care providers. The emphasis on protecting customer-facing roles in critical markets like the U.S. also signals a commitment to maintaining strong industry partnerships, recognizing that professional services are indispensable to the ultimate success of their innovative products.